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Abstract
Histone deacetylase inhibitors (HDACi) have demonstrated promising therapeutic potential in clinical trials for
hematological malignancies. HDACi, such as SAHA/Vorinostat, Trichostatin A, and MS-275 were found to induce apoptosis
of leukemic blasts through activation of the death receptor pathway and transcriptional induction of the Tumor Necrosis
Factor (TNF)-related pro-apoptotic family members, TRAIL and FasL. The impact of HDACi on TNF-related costimulatory
molecules such as 4-1BB ligand (4-1BBL/TNFSF9) is however not known. Following exposure to SAHA/Vorinostat,
Trichostatin A, and MS-275, transcript levels were determined by real time PCR in Jurkat, Raji and U937 cells. Treatment with
HDACi up-regulated TNFSF9 gene expression in the three leukemia cell lines, yet to different extend and with distinct
kinetics, which did not require de novo protein synthesis and was not associated with DNAse I hypersensitive chromatin
remodeling. Transcriptional activity of TNFSF9 promoter-luciferase constructs was induced up to 12 fold by HDACi, and
implication of Sp1/Sp3 transcription factors binding to functional GC-box elements was evidenced by reporter gene assays,
site-directed mutagenesis, and electrophoretic mobility shift assays. Functionality of modulated target genes was assessed
in allogeneic mixed leukocyte reaction experiments. MS-275- and to a lesser extent Trichostatin A- and SAHA-treated Raji
cells significantly up regulated T lymphocytes proliferation which was reduced by about 50% by a 4-1BB blocking
recombinant protein, while MS-275- but neither Trichostatin A- nor SAHA-treated cells up-regulated IFNc secretion by T
lymphocytes. Our results identify 4-1BBL/4-1BB as a downstream target of HDACi, especially of MS-275 anti-leukemia action
in vitro. Thus, HDACi such as MS-275 displaying dual TNF-dependent proapoptotic and costimulatory activities might be
favored for inclusion in HDACi-based anti-cancer therapeutic strategies.
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Introduction
Members of the Tumor Necrosis Factor ligands and receptors
Superfamily (TNFSF) are both secreted and membrane-bound
factors that regulate proliferation, activation, differentiation,
maturation and survival or programmed cell death of lymphoid,
myeloid and other haematopoietic, as well as various non-
haematopoietic cell types [1,2]. TNFSF are also implicated in
various acquired or genetic diseases, and have been diversely
involved in the control of carcinogenesis. While TNFa or
TNFR1,2/TNFRSF1A,1B targeting induce tumor development
resistance [3,4], TRAIL/TNFSF10 deficiency accelerates hema-
tological malignancies [5]. Furthermore, several TNFSF have
demonstrated significant antitumor potential in a number of pre-
clinical murine and human tumor models [6]. Notably, the finding
that agonistic 4-1BB monoclonal antibodies can greatly enhance
the expansion of CD8
+ T cells in vivo and eradicate established
tumors raised great interest in 4-1BB as a therapeutic target [7,8].
Hence, strategies that aim to control TNFSF functions are
intensively pursued, including the use of recombinant proteins,
specific monoclonal antibodies, and by gene transfer. Recently, the
tumor-selective action of histone deacetylase inhibitors (HDACi)
was shown to involve TRAIL induction in acute myeloid leukemia
cells [9,10], paving the road to drug-based antitumor therapeutic
strategies targeting TNFSF functions.
HDACi represent a new class of antitumor agents acting on
histone deacetylase (HDAC) enzymatic activity [11,12]. Despite the
widespread role of HDAC in the transcriptional regulation of gene
expression, HDACi are relatively non-toxic to normal cells both in
vitro and in vivo, allowing to their use in anti-cancer therapeutic
strategies. However, it remains unclear how HDACi exert this
cancer cell-selective activity. HDACi are able to induce cell cycle
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death of tumor cells [11–13]. Many HDACi have been identified,
including the hydroxamate compounds Trichostatin A (TSA) and
Suberoylanilide hydroxamic acid (SAHA) that are potent nanomo-
lar HDACi, and the benzamide derivative MS-275, a non
hydroxamate micromolar inhibitor of HDACs [13–16]. Previous
reports have shown that these HDACi up-regulate transcription of
the p21/WAF/CDKN1A cell-cycle inhibitor and induce TNFSF10
transcription, accounting for the in vitro HDACi-induced G1 arrest
and extrinsic apoptosis, respectively [9,10]. In vivo, knocking down
TNFSF10 impairs the antitumor effect of MS-275 [10], but
antitumor activity of HDACi may further involve additional
biological effects such as reduced angiogenesis [17] and inflamma-
tion [18], as well as increased immunogenicity [19,20].
In this study, we identified TNFSF9/4-1BBL as a HDACi target
that can mediate anti-leukemia allogeneic leukocyte response.
Materials and Methods
Cells, Culture condition
Jurkat T cells (JA16 clone), Raji cells and U937 cells were
maintained in RPMI 1640 medium supplemented with 10% fetal
calf serum. Drosophila melanogaster SL2 cells were maintained in
Insect-X-Press medium (BioWhittaker) supplemented with 10%
FCS at 25uC without CO2.
HDACIs and other reagents
Three HDACi were used in this study: Trichostatin A (TSA)
was obtained from Sigma, MS-275 and SAHA were obtained
from Alexis. Cycloheximide (CHX) and Mithramycin A (MA)
were obtained from SIGMA.
Plasmid constructs
The primers used for the pTNFSF9 constructs were:
pTNFSF9 (1), 59-CAGGGAGAGAGACACAGAGACAGAG-39;
pTNFSF9 (2), 59-GATCTCTTTCCACCCACTGCAGAGGC-39;
pTNFSF9 (3), 59-GACGAGGGGAAAGGCTCTGGG-39;
pTNFSF9 (4), 59-GGCCTCCTTTTGTAGCCAAGCAGC-39
and the 39 primer: 59-GACGAGAGACTGCGGGAAGACA-
CAGC-39. The PCR products were cloned into the reporter
vector pGL3-Basic adapted to the Gateway technology (a gift from
T.Virolle). Whole nucleotide sequences from these constructs were
confirmed by sequencing.
Site-directed Mutagenesis
pTNFSF9 (3) was used as a template for mutagenesis performed
by the QuickChange site-directed mutagenesis method (Strata-
gene). The primers used to obtain Sp points mutants are:
m1, 59-GGAAAGGCTCTGTTCTGGGAAGTTGCGTGTC-
CGCGGGCGGAGG-39;
m2, 59-GGGCGTGGCCGCGTTCGGAGTTGCGTTTCC-
GCGGGCGGAGG-39;
m3, 59-GGCGTGGCCGCGTTCGGAGTTGCGTTGCCT-
CCTTTTGTAGCC-39.
Mutations were confirmed by DNA sequencing.
RNA extraction and RT-PCR
Total RNA was isolated from the cells using the RNeasy mini
kit (Qiagen) according to the manufacturer’s protocol. 2 mg of total
RNA was reversed transcribed into cDNA. The expression of
TNFSF9 and GAPDH mRNA was analyzed by RT-PCR using the
following primers for TNFSF9: forward, 59-GTTTCACTT-
GCGCTGCACCTGCAGCCACTG-39 and reverse, 59-TATCA-
ACGTCCAACTTGGGGAAGG-39; and for GAPDH, forward,
59-GTCATCCCTGAGCTGAAC-39 and reverse, 59-GGGTCT-
TACTCCTTGGAG-39. Amplification was performed with de-
naturation at 94uC for 50 s, annealing at 60uC (for GAPDH)o r
65uC (for TNFSF9) for 45 s and extension at 72uC for 45 s. The
PCR products for TNFSF9 (466 bp) and GAPDH (613 bp) were
separated by electrophoresis on a 3% agarose gel and visualized by
staining with ethidium bromide.
Quantitative RT-PCR
Primer pairs for seventeen TNFSF ligands and twenty-four
receptors were incorporated into a low-density array (Assay on
Demand, Applied Biosystems). Three endogenous controls were
added to the assay set. Three genes were added that represent
genes previously described as being either up- or down-regulated
by HDACi (see Table 1 for a complete list of genes included in this
array). PCR was developed as recommended by the manufacturer.
Briefly, 5 ml cDNA (equivalent to 100 ng of total RNA) was mixed
with TaqMan Universal Mix (Applied Biosystems) and loaded into
1 sample port. Thermal cycler conditions were as follows: 2
minutes at 50uC, 15 s at 95uC, 60 s at 60uC for 40 cycles. Capture
of fluorescence was recorded on the ABI Prism 7900HT scanner,
and the CT was calculated for each assay using Sequence
Detection System Software 2.1 (Applied Biosystems). Normaliza-
tion of quantitative-PCR assays was conducted using the CT value
of the GAPDH endogenous control. Samples were then converted
to a fold change ratio described using standard D CT formula
where DCT=C T target – CT average endogenous controls.
Thereafter, DDCT values were calculated by subtracting the
Table 1. List of genes included in the quantitative RT-PCR
low-density array.
Ligands Receptors Housekeeping genes Control genes
LTa TNFR1 b-Actine p21WAF1/CIP1
TNFa GAPDH IFNc
LTb LTbR HPRT ErbB2/Her2
OX40L OX40 c-Myc
CD40L CD40
FasL Fas
CD27L CD27
CD30L CD30
4-1BBL 4-1BB
TRAIL DR4
DR5
DcR1
DcR2
RANKL RANK
OPG
TWEAK Fn14
APRIL TACI
BAFF BAFFR
LIGHT HVEM
TL1A DR3
GITRL GITR
TROY
EDAR
doi:10.1371/journal.pone.0007085.t001
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(untreated samples). Clustering of quantitative-PCR data was
conducted by Pearson correlation and visualized using the
program TIGR Multiexperiment Viewer (MeV) (http://www.
tigr.org/software/tm4/mev.html) [47].
Real time quantitative PCR was performed using a LightCycler
rapid thermal cycler (Roche) according to the manufacturer’s
conditions. Primers for TNFSF9 and GAPDH used were from
Applied Biosystems (TaqManH Gene Expression Assays).
Flow cytometry analysis
The cells were treated with HDACi for 4, 8, 24 and 48 h before
flow cytometric analysis. Briefly, 2610
5 cells were incubated with
anti-mouse IgG-PE (Beckman Coulter) or anti-4-1BBL antibodies
(BD Pharmingen) at 4uC for 30 minutes. After three washes with
phosphate-buffered saline (PBS) supplemented with 2% FCS, the
cells were subjected to flow cytometric analysis. Samples were
analyzed on a FACScan (Becton Dickinson) and analyzed by
CellQuest software.
Nuclease digestion of purified nuclei and southern
blotting
Nuclei were purified and submitted to nuclease digestion as
previously described [21]. Briefly, cells were lysed at 4uC in 0.2%
NP40 buffer followed by nuclease digestion using DNase I (10 min
at 4uC). Proteinase K-treated DNA was next purified by phenol
extraction. Purified DNA (30 mg) was digested with Sac I and the
fragments generated were separated by electrophoresis. Each size
marker was generated by digesting genomic DNA (10 mg) with
restriction enzymes as indicated in figure legends. After transfer to
nylon membranes (Hybond-N+, Amersham Pharmacia Biotech),
DNA was UV-cross-linked and membranes were prehybridized, as
previously described [21]. The specific probes were synthesized by
PCR using the following primer pairs: 59-CTGCTGATC-
GATGGGCCCCTGAGC-39 and 59-GACCTCGGTGAAGG-
GAGTCCGGCTG-39. After random primer labeling, denatured
DNA probes were allowed to hybridize for at least 16 h at 68uC
followed by extensive washes and autoradiography.
Electroporation and Luciferase Assays
10
7 Jurkat T cells were electroporated using Bio-Rad gene
pulser II (250 V, 25 ms) with 10 mg of pGL3 or the various
TNFSF9 promoter-driven firefly luciferase constructs together with
5 mg of beta-globine Renilla luciferase plasmid (pRL-b). The cells
were incubated for 1 h before they were collected, washed in PBS
and lysed to determine the luciferase activity by using the dual
luciferase reporter assay according to manufacturer’s instructions
(Promega), and read using a luminometer (Dynex). The transfec-
tion efficiency was normalized to Renilla luciferase activity and
corrected for protein content as determined by the Bradford
protein assay (Bio-Rad). The reported values represent the average
of three independent transfections, with standard deviation as
errors bars.
SL2 cells (2610
5) were plated in 24-well plates and transfection
was carried out using Effectene Transfection Reagent (Qiagen).
Each well was transfected with 200 ng of reporter plasmid and
with pHMW-Sp1 (0 to 600 ng) supplemented, when necessary,
with empty vector (pHMW) to equalize the total DNA transfected
to 1 mg. Fourty-eight hours after transfection, cells were harvested
and assayed for luciferase activity as described above. Human
pHMW-Sp1 and its control vector (pHMW) were gifts from Dr
Murphy, T.D, Carnegie Institution of Washington, USA.
Allogeneic mixed leukocyte reaction
Raji cells were treated for 24 hours with TSA (250 nM), MS-275
(2.5 mM) or SAHA (2.5 mM). After irradiation, 1610
5 stimulator B
lymphomas cells (Raji) were added to 2610
5 PBMCs in each well of
96-well U-bottomed culture plates. OKT3 (0.5 mg/ml) was
immobilized onto the surface of the plates (ON, 4uC). Cells were
cultured in presence or absence of 1 mg/ml recombinant human
4-1BB-FcandDR3-Fc(R&D systems)orcontrolNectine 4-Fc(agift
fromM.Lopez).Recombinantproteinswereaddedtotheculturesat
the same time as cells. Lymphocyte proliferation after 5 days of
culture was measured by adding [
3H]-thymidine (0,2 mCi/well) to
the wells for the last 18 h and the cells were harvested. [
3H]
incorporation was determined using a TopCount scintillation
counter (Packard Instrument).
Cytokine assay
IFN-c levels were measured by ELISA using a cytokine
detection kit (BD Biosciences) according to the manufacturer’s
instructions.
Electrophoretic mobility shift assays
Nuclear extracts were prepared by a rapid method described
by Osborn et al [22]. All buffers contained complete protease
inhibitors (Roche). Protein concentrations were determined by
the method of Bradford [23]. The DNA sequences of the coding
strand of the double-stranded oligonucleotides used for this study
are listed in Table 2. Electrophoretic mobility shift assays
(EMSAs) were performed as described previously [24]. Briefly,
nuclear extract (10 mg of protein) was first incubated on ice for
10 min in the absence of probe and specific competitor DNA in a
16 ml reaction mixture containing 10 mgo fD N a s e - f r e eB S A
(Amersham Biosciences), 1–2 mg of poly(dI–dC) (Amersham
Biosciences) as non-specific competitor DNA, 50 mM ZnCl2,
0.25 mM DTT, 20 mM HEPES (pH 7.3), 60 mM KCl, 1 mM
MgCl2, 0.1 mM EDTA and 10% (v/v) glycerol. 20 000 c.p.m. of
probe (10–40 fmol) was then added to the mixture with or
without a molar excess of an unlabeled specific DNA competitor,
and the mixture was incubated for 20 min on ice. Samples were
subjected to electrophoresis at room temperature on 6%
polyacrylamide gels at 120 V for 2–3 h in 1x TGE buffer
(25 mM Tris–acetate, pH 8.3), 190 mM glycine and 1 mM
EDTA). Gels were dried and autoradiographed for 24–48 h at
270uC. For supershift assays, polyclonal antibodies against Sp1
(sc-059X), Sp2 (sc-643X), Sp3 (sc-644X), Sp4 (sc-645X), (Santa
Cruz Biotechnology), or a purified rabbit immunoglobulin (IgG)
were added to the reaction mixture and incubated for 30 min on
ice before the addition of the radiolabeled probe.
Table 2. Primers used for Electrophoretic Mobility Shift
Assays.
GC box1 wt: 59-GGA AAG GCT CTG GGC TGG GAA GGG GCG TGG CCG CGG-39
GC box1 mut: 59-GGA AAG GCT CTG TTC TGG GAA GTT GCG TGT CCG CGT-39
GC box2 wt: 59-TGG CCG CGG GCG GAG GGG CGT GGC CGC GG-39
GC box2 mut: 59-TGT CCG CGT TCG GAG TTG CGT TTC CGC GT-39
GC box3 wt: 59-TGG CCG CGG GCG GAG GGG CGT GGC CTC CTT-39
GC box3 mut: 59-TTT CCG CGT TCG GAG TTG CGT TGC CTC CTT-39
(Only forward primers are indicated).
doi:10.1371/journal.pone.0007085.t002
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Up-regulation of TNFSF9 mRNA in HDACi-stimulated
leukemia cell lines
Modification of histone and a tubulin acetylation by HDAC
inhibition was first investigated in the Jurkat T cell leukemia cell
lines using different treatment times and dosages of the hydro-
xamic-derived Trichostatin A (TSA), the Suberoylanilide hydro-
xamic acid (SAHA), and the benzamide-derived MS-275 HDACi.
As shown in Fig. 1A, while the three HDACi induced dose-
dependent acetylation of histone H4, which peaked at 16 hours of
treatment, only SAHA and TSA induced a tubulin acetylation, as
expected from the known incapacity of MS-275 to impact on the
specific acetylation of a tubulin by HDAC 6.
These experimental conditions were developped to investigate
for the transcriptional modulation of genes of the TNFSF familly
using a transcription low-density array (see list of genes in Table 1).
Modification of TNFSF mRNA profiles induced by 8 h treatment
with TSA, SAHA, and MS-275 were determined in Jurkat cells,
followed or not by a 4 h stimulation by a combination of phorbol
ester (PMA) and calcium ionophore (Ionomycin) to up-regulate
gene transcription. As compared to untreated cells, each HDACi
strongly induced p21/WAF/CDKN1A cell cycle inhibitor, used
here as control for HDACi-regulated gene transcription (Fig. 1B).
Significant (above 2-fold and up to 15-fold) modifications of
TNFSF transcript levels were also noted, consistent with previous
reports (not shown [12,25]). Interestingly, TNFSF9 was the only
TNFSF out of the 17 TNFSF present in the array to be modulated
by the three HDACi (not shown). Indeed, as showed in Fig. 1B,
the three investigated HDACi up-regulated mRNA levels of
TNFSF9 by two- to eight-fold, but not HPRT and b Actin mRNA
levels, as normalized to GAPDH levels. Transcriptional induction
by the combination of PMA and Ionomycin further increased
HDACi-induced TNFSF9 mRNA levels, which was confirmed by
RT-PCR analysis (Fig. 1C), as well as by quantitative real time
RT-PCR (data not shown). Time course RT-PCR experiments
further showed that TNFSF9 mRNA levels were up-regulated by
the three HDACi in Jurkat and also in the Raji Burkit B
lymphoma and U937 myeloid cell lines, in a time-dependent
manner, as compared to endogenous GAPDH levels, yet with
distinct kinetics (Fig. 1D).
Up-regulation of TNFSF9 by HDACi does not require de
novo protein synthesis and is not associated with DNAse
I hypersensitive chromatin remodeling
To explore the mechanism of HDACi-induced TNFSF9 up-
regulation, Jurkat cells were pre-incubated with the protein
synthesis inhibitor, cycloheximide (CHX) followed by further
incubation for 8 h in the presence or absence of HDACi. As
shown in Fig. 2A, TNFSF9 mRNA levels were not reduced by
CHX treatment, but instead were observed to be markedly up-
regulated. This was further confirmed by QRT-PCR (Fig. 2B),
suggesting that TNFSF9 mRNA levels are regulated by neosynthe-
sized cellular factors. However, this effect appeared to not be
modulated by HDAC inhibition (Fig. 2A and 2B), indicating that
the observed upregulation of TNFSF9 mRNA levels by HDACi
does not appear to require neosynthesized cellular factors, and
suggests the direct implication of transcriptional regulatory
mechanisms. In eukaryotes, chromatin is recognized as an
important modulator of transcriptional regulatory mechanisms
[26]. Increased histone acetylation, such as following HDAC
activity pharmacological inhibition, neutralizes the positive charge
of lysine residues, allowing a more ‘‘open’’ chromatin structure
that facilitates transcription. We thus investigated whether the
upregulation of TNFSF9 mRNA levels by HDACiinvolved chromatin
remodeling. DNAse I digestion of the TNFSF9 locus followed by
indirect end-labeling identified two major dose-dependent DNase
I hypersensitive sites (DHSI and II) that were mapped to the 59
regulatory promoter region and between exon 1 and exon 2
(Fig. 2C), respectively. This pattern remained unchanged following
HDACi treatment, indicating that the modulation of TNFSF9
mRNA levels by HDACi expression does not involve detectable
DNAse I hypersensitive chromatin remodeling within the region
under study, however, this study does not exclude localized
promoter architecture modifications. The hypersensitivity of the
promoter region to DNAse I digestion in unstimulated cells
correlated with the basal constitutive transcription of TNFSF9 in
Jurkat T cells (data not shown).
Identification and mapping of HDACi responsive
elements within the TNFSF9 promoter region
To determine whether HDACi activate TNFSF9 transcription,
we isolated human genomic fragments containing the predicted
TNFSF9 59 regulatory regions (Fig. 3A). These genomic DNA
fragments were inserted upstream to the luciferase reporter gene in
the pGL3 basic plasmid construct (Fig. 3B). Promoter activity of
the corresponding constructs (pTNFSF9 (1)-(4)) was assayed by
measuring firefly luciferase activity after transient transfection in
Jurkat T cells (Fig. 3C). pTNFSF9(1), pTNFSF9(2) and pTNFSF9(3)
transcriptional activity was induced up to 12 fold by TSA
treatment, indicating the presence of TSA-inducible element(s)
within the 985, 398 and 140 bp genomic DNA fragment
controlling firefly luciferase transcription (Fig. 3C). In contrast,
firefly luciferase activity was not induced by TSA treatment of cells
transfected with the pTNFSF9(4) or pGL3 basic empty constructs,
indicating that these TSA-inducible element(s) are contained
between nucleotide –140 and –65 according to the translation
initiation site (Fig. 3). Similar results were observed using different
HDACi in different cell lines (data not shown).
Identification of HDACi responsive elements within the
TNFSF9 promoter region
Previous studies have shown that conserved cis-regulatory
elements, particularly Sp1 and CCAAT boxes, located in the
promoters of several genes are responsible for transcriptional
activation by HDACi [27–32]. Sequence analysis of the pTNFSF9
region contained between the nucleotides 2140 and 265 upstream
to the translation initiation site using MatInspector (Genomatix
Software, Munich, Germany) and TESS (Transcription Element
Search System, CBIL, US) allowed the identification of consensus
binding sites for transcriptions factors of the Sp (GC-box) family
(Fig. 3A). Mutations of the individual GC-box, as well as combined
mutations were performed to evaluate the functional significance of
these putative Sp binding sites. As shown in Fig. 4A, individual
mutations did not significantly alter basal promoter activity, yet
TSA-activated pTNFSF9(3) promoter luciferase activity was re-
duced by about 25–70% in Jurkat T cells, depending on the
individual mutated GC-rich sequence, whereas the combined
mutation (pTNFSF9(3) m4) abolished both the basal- and the
TSA-induced activity, as compared to the control pGL3 basic
reporter construct. Similar results were obtained upon transfection
of the pTNFSF9(3) and pTNFSF9(3) m4 promoter constructs in the
U937 and Raji cell lines (Fig. 4B). These results identify the GC-
boxes studied as important mediators of HDACi inducibility of
TNFSF9 promoter activity. To gainmore insights intothe specificity
of GC-rich sequences in TSA-induced transcription, a previously
described p-486TNFSF6/FasL promoter construct containing
Regulation of 4-1BBL by HDACi
PLoS ONE | www.plosone.org 4 September 2009 | Volume 4 | Issue 9 | e7085Figure 1. Analysis of TNFSF9 gene expression profiles induced by HDACi in leukaemia cell lines. (A) Jurkat JA16 cells were incubated with
SAHA (lanes 2–5; 0.5, 1, 2.5 and 5 mM), MS-275 (lanes 6–9; 0.5, 1, 2.5 and 5 mM) or TSA (lanes 10–13, 50, 100, 200, 500 nM), or mock-treated (lane 1) for
16 hours, followed by cell lysis, SDS-PAGE and immunoblotting using the indicated antibodies (left panel). In parallel, Jurkat JA16 cells were incubated
with SAHA (2 mM), TSA (200 nM), MS-275 (2 mM) or mock-treated (DMSO) for 6, 16 or 24 hours, as indicated, followed by cell lysis, SDS-PAGE and
immunoblotting using the indicated antibodies (rightpanel). (B) JurkatJA16 cellswere incubated with TSA (500 nM),MS-275(2,5 mM) or SAHA (2,5 mM)
for 8 hours and left unstimulated or stimulated by PMA (20 ng/ml) and Ionomycin (1 mg/ml) for 4 hours. Following incubation time, total mRNA was
extractedandanalyzed byTranscriptionLow DensityArray.ResultsobtainedforHPRT, bActin, p21/WAF/CDKN1A andTNFSF9arepresented asexpression
ratios relative to GAPDH transcript levels. The scale shows the level of expression, where red indicates increased gene expresssion, and the intensity of
color correlated to the magnitude change. Black indicates no change. (C) mRNA from (B) were analyzed by RT-PCR, using TNFSF9 and GAPDH primer
pairs. (D) JurkatJA16, RAJI andU937 cells were mock-treated or incubated with TSA (250 nM), MS-275 (1 mM) andSAHA (1 mM)for4,8 or 24 hours. Total
mRNA was extracted and transcripts of TNFSF9 and GAPDH were analyzed by RT-PCR. These conditions were compromized to compare for TNFSF9
transcript detection and modulation by HDAC inhibition in different cell types producing distinct basal TNFSF9 transcript levels.
doi:10.1371/journal.pone.0007085.g001
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PLoS ONE | www.plosone.org 5 September 2009 | Volume 4 | Issue 9 | e7085Figure 2. Modulation of TNFSF9 transcript levels by HDACi does not require de novo protein synthesis and does not require TNFSF9
promoter region chromatin remodeling. Jurkat JA16 cells were left unstimulated (UN) or were incubated for 1 hour with CHX (10 mg/ml) and then
treatedfor8 hours byTSA(250 nM),MS-275(1 mM)andSAHA(1 mM).TotalmRNAwas extractedandtranscriptsofTNFSF9andGAPDHwereanalysedby
PCR (A) and quantified by real-time PCR (B) as described in Fig. 1. (C) Nuclei from Jurkat T cells left unstimulated (UN), or treated with TSA (500 nM) for
18 hours, were digested in vivo with increasing amounts of DNase I (0, 30, 40, 50, 60 and 70 U/ml) followed by SacI digestion in vitro and indirect end-
labeling (lower panel). The schematic organization of the TNFSF9 locus, showing the indirect end-labeling and southern blotting strategy, as well as the
DNaseI hypersensitive sites (DHS) identified in the course of the present study are depicted in the upper panel. The position of the probe used for the
southern blotting, as well as the TNFSF9 exon 1-3 are showed. Hypersensitive regions DHSI and DHSII are shown on the left. Molecular weight markers
(MM) are a double digest of naked DNA by SacI (12641 bp), NsiI (9180 bp), NheI (6850 bp), HincII (5006 bp), XhoI (2390 bp) and BglII (1918 bp).
doi:10.1371/journal.pone.0007085.g002
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PLoS ONE | www.plosone.org 6 September 2009 | Volume 4 | Issue 9 | e7085Figure 3. Identification of TSA response elements in the human TNFSF9 promoter. (A) DNA sequence of a 400-bp human TNFSF9 promoter
region. The ATG site is boldface (to which we assigned the position nucleotide + 1). Putative Sp1/Sp3 binding sites are boxed. Putative CCAAT boxes
are underlined. (B) The constructs were generated by cloning progressively 59-truncated human TNFSF9 promoter fragments into the pGL3/basic
luciferase vector. Negative numbers denote bp distances from translational start codon. (C) Jurkat cells were transiently cotransfected with the
indicated reporter constructs and pRL-b to control for transfection efficiency. Transfected cells were either left untreated or treated with TSA (500 nM)
for 16 hours. Data are the average 6 SD of three independent experiments. RLU, relative light units.
doi:10.1371/journal.pone.0007085.g003
Regulation of 4-1BBL by HDACi
PLoS ONE | www.plosone.org 7 September 2009 | Volume 4 | Issue 9 | e7085Figure4.TSA-inducedTNFSF9 promoteractivitydepends onGC-boxessequences. (A) Thedifferent pTNFSF9 (3)-lucmutatedconstructs were
generated as described under ‘‘Materials and Methods’’. The hatched boxes represent putative GC-boxes. The mutations in theses sites are symbolized
by filled boxes. Jurkat cells were transiently cotransfected with the indicated reporter construct and the pRL-b to control for transfection efficiency. Cells
were left unstimulated or treated with TSA (500 nM) for 16 hours. Means 6 SD of three independent experiments are shown. Basal transcriptional
activities were 7.761.8, 13.564.9, 96.7619.2, 222.2620.3, 133.567.6 and175681.7 RLU for the pGL3, pTNFSF9 (3) m4, pTNFSF9 (3) m3,pTNFSF9 (3) m2,
pTNFSF9 (3) m1 and pTNFSF9 (3), respectively. (B) The indicated pTNFSF9 (3)-luc constructs were transfected in U937 (left panel) and Raji (right panel)
cell lines and analyzed as described in (A). (C) The p-486TNFSF6/FasL promoter construct was transfected in Jurkat cells and analyzed as described in (A)
except that PMA (20 ng/ml) and Ionomycin (1 mg/ml) were added, as indicated. Means 6 SD of three independent experiments are shown. (D) RT-PCR
was performed on total mRNA isolated from Jurkat cells pretreated with the GC-box binding inhibitor mithramycin A (MA) for 1 hour followed by
incubation in the presence TSA (250 nM) for 8 hours. (E) Increasing concentrations of MA (100, 200 and 500 nM) was added to the cells 1 hour after
transfection with the pTNFSF9 (3) reporter plasmid, followed by the addition of TSA (500 nM) 1 hour later. The cells were harvested 16 hours after the
addition of TSA and processed for luciferase assay. Means 6 SD of three independent experiments are shown.
doi:10.1371/journal.pone.0007085.g004
Regulation of 4-1BBL by HDACi
PLoS ONE | www.plosone.org 8 September 2009 | Volume 4 | Issue 9 | e7085functional GC-rich sequences was transfected into Jurkat cells and
analyzed for its responsiveness to TSA treatment ([21,33]). As
shown in Fig. 4C, despite transcriptional induction of this promoter
constructbyPMAplusIonomycintreatment,TSAdidnotstimulate
p-486TNFSF6/FasL-mediated transcription. On the opposite,
TSA co-treatment down-regulated PMA plus Ionomycin-induced
transcription, indicating that the presence of functional GC-rich
sequences does not predict TSA-responsiveness (Fig. 4B).
Effect of the mithramycin A DNA intercalating agent on
HDACi-induced TNFSF9 gene expression
Mithramycin A is an anti-tumor antibiotic which inhibits
transcription from promoters containing GC-rich DNA sequences
[34,35]. We thus evaluated HDACi-induced TNFSF9 expression
following mithramycin A treatment. As shown in Fig. 4C,
mithramycin A prevented TSA-induced TNFSF9 mRNA up-
regulation. Consistent with the decreased levels of TNFSF9
mRNA, mithramycin A also reduced TSA-induced pTNFSF9(3)-
mediated transcriptional activity in a dose-dependent manner
(Fig. 4D). Collectively, this data strongly indicates that GC-box
interacting transcription factors are involved in HDACi-induced
TNFSF9 expression.
Sp1/Sp3 transcription factors bind to TNFSF9 promoter
GC box elements in vitro and increase its promoter
activity
In order to assess the binding of members of the Sp family to the
GC-boxes that we identified in the TNFSF9 promoter region, we
designed double-stranded oligonucleotides (Fig. 5A). These
oligonucleotides were radiolabeled and tested in electrophoretic
mobility shift assays (EMSA) for DNA–protein interactions with
nuclear extracts from mock-treated and TSA-treated Jurkat cells
(Fig. 5B). Retarded protein–DNA complexes were observed using
the three distinct GC-box oligonucleotides and TSA treatment did
not induce detectable modification of the observed pattern of
retarded protein-DNA complexes. To evaluate the sequence
specificity of the binding to these GC-boxes, we performed
competition EMSAs using different unlabeled double-stranded
competitor oligonucleotides (Fig. 5C). The specificity of the
protein binding was demonstrated because their formation was
inhibited by competition with molar excesses of the unlabeled
homologous oligonucleotides (Fig. 5C, lane 3). In contrast, these
complexes were not competed by mutated version of the
oligonucleotides (lane 4). Similar results were observed for the
three GC-boxes. To identify directly the Sp family members
within the retarded complexes, we performed supershift assays
using specific antibodies directed against individual members of
the Sp family of transcription factors (Fig. 5D). The wild-type
probe was incubated with nuclear extracts from Jurkat cells and
polyclonal antibodies directed against Sp1 and/or Sp3 were added
to the binding reaction mixture. The Sp1 antibody selectively
supershifted the major slower migrating complex (Fig. 5D, lane 3)
and the Sp3 antibody resulted in the strong decrease of the faster
migrating complex (Fig. 5D, lane 4). We confirmed these results
when both the anti-Sp1 and anti-Sp3 antibodies were included in
the same binding reaction (Fig. 5D, lane 5). In contrast, the
binding pattern was not affected by the addition of the antibodies
directed against other Sp proteins (Sp2 and Sp4) (data not shown),
showing that the two complexes did not seem to involve these
other proteins. Moreover, the binding pattern was not affected by
the addition of purified IgG, used as a negative control (Fig. 5D,
lane 6). Again, similar results were obtained using the three GC-
boxes. Of note, TSA treatment did not appear to detectably alter
Sp1 and/or Sp3 binding (Fig. 5D). Overall, these results
demonstrate that Sp1 and Sp3 transcription factors interact with
the GC-box (renamed Sp site hereafter in the manuscript) located
in the TNFSF9 promoter region. SL2 cells are devoid of
endogenous human Sp family transcription factors and thus
represent a useful model to investigate Sp-dependent transcrip-
tional mechanisms [36,37]. SL2 cells were cotransfected with the
pTNFSF9(3) promoter construct along with pHMW-Sp1 (insect
expression vectors encoding for human Sp1). Over expression of
Sp1 in SL2 cells resulted in an increased expression of the
pTNFSF9(3) promoter construct in a dose-dependent manner
(Figure 5E). Similar results were obtained upon expression of Sp3
transcription factor (not shown).
HDACi-induced TNFSF9 expression increases anti-
leukemia allogeneic leukocyte response
In an attempt to determine the functional significance of HDACi-
induced TNFSF9 mRNA levels, 4-1BBL protein expresssion levels
and function were evaluated. Time course Flow Cytometry
experiments evidenced the up-regulation of 4-1BBL cell surface
expressionbythethreeHDACiinRajicells(Fig.6A).Raljicellswere
next incubated in the presence of HDACi for 24 hours followed by
c-irradiation to prevent further cell proliferation and co-culture with
purified T lymphocytes from healthy donors. IFNc secretion was
determined by ELISA and T lymphocyte proliferation was assessed
by[
3H]-thymidineuptake.MS-275-stimulatedRajicellssignificantly
up-regulated IFNc secretion by7 fold (t student, p,0,01), which was
prevented by the recombinant 4-1BB-Fc but not control-Fc protein
(Fig.6B),indicatinga requirementfor4-1BB/4-1BBLinteractionfor
IFNc secretion stimulated by HDACi-treated Raji cells. TcR/CD3
triggering to activate T lymphocytes to up-regulate cell surface
4-1BB [38–40], induced a marked up-regulation of IFNc secretion
which was further significantly increased by co-culture of stimulated
T cells with MS-275-stimulated Raji cells as compared to untreated
Raji cells (6675,86409,3 pg/ml versus 4607,46167,4 pg/ml;
ts t u d e n t :p ,0,01), in a 4-1BB/4-1BBL interaction dependent-
manner (Fig. 6B). In contrast to MS-275, TSA- and SAHA-
stimulated Raji cells did not stimulate increased IFNc secretion
(Fig. 6B). However, HDACi-stimulated Raji cells significantly up-
regulated T cell proliferation, as compared to untreated Raji cells,
using either TSA and SAHA (t student, p,0,05) or MS-275
(t student, p,0,01) (Fig. 6C). Addition of the recombinant 4-1BB-Fc
but not control-Fc protein efficiently prevented up-regulation of T
lymphocyte proliferation by HDACi-stimulated Raji cells, implicat-
ing 4-1BB/4-1BBL interactions in the increased proliferation
(Fig. 6C). To further examine for the specificity of 4-1BB/4-1BBL
interactions in this HDACi-stimulated mixed lymphoid reaction,
DR3-Fc recombinant protein was used as an additional control.
Indeed,TL1A/TNFSF15-DR3 interactionshavebeen implicated in
T cell proliferation and IFNc secretion [41]. Using the DR3-Fc
recombinant protein to block these interactions, only 4-1BB-Fc, but
neither the control-Fc nor the DR3-Fc recombinant proteins
efficiently prevented up-regulation of T lymphocyte proliferation
by HDACi-stimulated Raji cells, specifically implicating 4-1BB/
4-1BBL interactions in the increased proliferation (Fig. 6E)
Discussion
In this study, we identified 4-1BBL/TNFSF9 as a transcriptio-
naly activated target of three distinct HDACi in leukemia cell lines
and most importantly that MS-275-induced 4-1BB/4-1BBL
interactions potentiated anti-leukemia allogeneic leukocyte re-
sponse, hence providing novel molecular insights into the
antileukemia mechanisms of action of HDACi.
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antitumor activities [42–44]. Expression profiling studies have
identified that limited sets of target genes (2–10%) are regulated
by HDACi [45–48], yet more recent studies have suggested that
this number might have been underestimated [43]. Nonetheless,
the molecular basis to explain how HDACi impact gene
expression remains poorly understood at the genome level. As
previously described for CDKN1A/p21/WAF [49], TNFSF10 [10]
and other HDACi-activated genes [50], we show here that the
TNFSF9 promoter region contains functional Sp1/Sp3 transcrip-
Figure 5. Sp proteins bind to the GC-box located in the TNFSF9 promoter. (A) Nucleotide sequence of the three wild-type GC-box
oligonucleotides probes are shown with underlined bases corresponding to the mutated bases. (B) The three wild-type GC-box oligonucleotides
probes were incubated with nuclear extracts from Jurkat cells (10 mg) and treated or not for 4 hours with TSA (250 nM) in the absence or in the
presence of unspecific competitor (dI-dC). The figure shows only the specific retarded bands of interest. (C) The three wild-type GC-box
oligonucleotide probes were incubated with nuclear extracts from Jurkat cells (10 mg) in the absence (lane 2) or in the presence of the unlabeled
oligonucleotide (lane 3) or of the mutated unlabeled oligonucleotide (lane 4). The figure shows only the specific retarded bands of interest. (D)
Nuclear extracts from Jurkat cells treated or not for 4 hours with TSA (250 nM) were incubated in the absence of antibody or in the presence of
antibodies directed against Sp1 and/or Sp3 (as indicated at the top of each lane) or with purified rabbit IgG as negative control, before addition of the
oligonucleotide probe. The figure shows only the specific retarded bands of interest. Arrows indicate specific retarded DNA-protein complexes
corresponding to Sp1 and Sp3. (E) SL2 cells were transiently cotransfected with pGL3 or pTNFSF9 (3)-luc and with various amounts of the Sp1
expression construct (pHMW-Sp1) or the empty vector (pHMW) and processed for luciferase assays. Values were normalized relative to the protein
concentration of the cellular lyzates. The experiment was repeated three times with similar results. RLU, relative light units.
doi:10.1371/journal.pone.0007085.g005
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PLoS ONE | www.plosone.org 10 September 2009 | Volume 4 | Issue 9 | e7085Figure6. Induced proliferation ofnormal allogeneic leukocytes by Raji cells treated with HDACi.(A) FACS analysisof 4-1BBL expression on
HDACi-treated Raji cells for 4, 8, 24 and 48 hours as indicated. Results are presented as % of positive cells. The data shown are from one experiment
representative of a total of two. (B) PBMCs (2610
5) of healthy donor were incubated for 5 days with Raji cells (1610
5) treated or not for 24 hours with
TSA (250 nM), MS-275 (2.5 mM) or SAHA (2.5 mM). PBMCs were stimulated or not with immobilized OKT3 (0,5 mg/ml) in the presence or absence of
recombinant human 4-1BB-Fc (1 mg/ml) or control-Fc protein (1 mg/ml), as indicated, and proliferation was measured by incorporation of
3H-thymidine
duringthelast 18 hours ofculture. Supernatants from unstimulated (C) andfrom OKT3-stimulated(D)cell cultureswere collected at48 hours ofculture
andassayedforIFNcbyELISA.Valuesaremeansoftriplicates6SDandthisexperiment isrepresentativeoftwoindependentexperiments.*p,0,05and
** p,0,01 (t student). (E) As in (B), except that DR3-Fc recombinant protein was added (1 mM/ml), as indicated. Values are means of triplicates 6 SD.
doi:10.1371/journal.pone.0007085.g006
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gene transcription. But how Sp1/Sp3 transcription factors
modulate TNFSF9 transcription in an HDACi-regulated manner
remains to be established. Using the indirect-end labeling
technique, DNAse I hypersensitive sites (DHSI and II) were
identified, DHSI being mapped to the TNFSF9 minimal
promoter region containing the Sp1/Sp3 DNA binding sites.
DHSI was detected in unstimulated Jurkat cells displaying basal
TNFSF9 transcription and was not detectably altered upon
HDACi treatment, in agreement with the transcriptional
activation of TNFSF9 promoter constructs by HDACi and
suggesting that HDACi-induced TNFSF9 transcription did not
involve DNase I-sensitive large chromatin remodeling events.
The transcriptional activity of Sp1 family members can be
modulated by acetylation [13,51,52] and both Sp1 and Sp3 can
interact with HDAC [53], suggesting a role for Sp1 and/or
Sp3 acetylation in the Sp1/Sp3-dependent, HDACi-regulated
TNFSF9 induction. Alternatively, Sp1/Sp3 may recruit acetylat-
ed co-factors allowing TNFSF9 transcriptional induction. To asses
the in vivo binding of Sp factors to the TNFSF9 promoter region,
we attempted to perform chromatin immunoprecipitation assays.
Preliminary experiments showed low enrichement of the TNFSF9
promoter region in Sp1 immunoprecipitates, as compared to
control antibodies, that were also not detectably modified by TSA
treatment in agreement with previous observations ((Nebbioso,
2005 #173] and data not shown).
Of interest, nonetheless, mithramycin A abrogated both
HDACi-stimulated endogenous and promoter-driven TNFSF9
transcription, yet it did not affect basal TNFSF9 transcription,
supporting the hypothesis that acetylation of Sp1/Sp3 or
associated factors, and not per se Sp1/Sp3 chromatin-recruitment,
was required for HDACi-regulated TNFSF9 induction. Consistent
with this hypothesis, EMSA experiments did not reveal increased
Sp1/Sp3 DNA binding upon HDACi treatment. Collectively,
these results support a model where protein acetylation induced by
HDACi increases the transcriptional activity of Sp1/Sp3-depen-
dent complexes seated on the TNFSF9 promoter. The mechanisms
of acetylation of Sp1/Sp3 or associated factors in HDACi-induced
TNFSF9 transcription remains to established.
One important finding of the present study was the functional
up-regulation of 4-1BBL by MS-275, as evidenced by enhanced
T cell proliferation and IFNc production in mixed peripheral
blood leukocytes co-culture experiments. While TRAIL up-
regulation was convincingly shown to contribute to the selective
HDACi-induced apoptosis of tumor cells, our results provide first
evidence that up-regulated 4-1BBL might further contribute to
the in vivo anticancer action of HDACi such as MS-275. There
has been ample evidence demonstrating the robust in vivo anti-
tumor immune responses upon 4-1BB triggering [6,7]. This effect
is largely interpreted by 4-1BB signaling on tumor-specific T cells
that can enhance proliferation and CTL activity, and can prevent
activation-induced cell death [8,40]. Consistently, co-cultures
of HDACi-treated Raji cells with T cell receptor-stimulated
peripheral blood leukocytes enhanced T cell proliferation as
compared to untreated Raji cells. This proliferative response was
blocked in the presence of competing 4-1BB-Fc, but not by DR3-
Fc recombinant protein, showing that 4-1BB/4-1BBL interaction
was specifically required for this HDACi-enhanced T cell
proliferative response. More recent studies have further revealed
additional mechanisms that may account for 4-1BB anti-tumor
effects. Firstly, 4-1BB signaling is able to prevent and rescue T
cells from immune tolerance, promoting regression of poorly
immunogenic tumors [54]. Secondly, 4-1BB expression on non-T
cell populations, including natural killer cells and dendritic cells
has been implicated [55,56]. Finally, 4-1BB stimulation modifies
the distribution pattern of tumor-specific T cells in vivo,i na
manner that is largely dependent on IFNc [57]. IFNc,a
pleiotropic cytokine secreted by activated T cells and NK cells,
plays a central role in both the innate and adaptive immune
response to a variety of pathogens and transformed cells [58].
CD4
+ and CD8
+ T cells have been shown to mediate tumor
rejection in an IFNc-dependent fashion through different
mechanisms, including up-regulation of molecules critical for
antigen processing and presentation [59], differentiation of fully
competent effector cells [60], secretion of angiostatic chemokines
by stromal cells present within a tumor [61], and regulation of T-
cell migration to the tumor site [62]. In this study, co-cultures of
MS-275-treated Raji cells with T cell receptor-stimulated
peripheral blood leukocytes enhanced T lymphocyte IFNc
secretion, as compared to untreated Raji cells. Increased IFNc
secretion was blocked in the presence of competing 4-1BB/
TNFRSF9-Fc recombinant protein, showing that 4-1BB/4-1BBL
interactions were required. Importantly, induction of IFNc was
also observed in the absence of T cell activation, and was
completely blocked in the presence of the 4-1BB-Fc recombinant
protein, indicating that induction of IFNc by MS-275-treated
Raji cells occurred through 4-1BB triggering and could occur in
the absence of T cell activation.
Despite similar levels of induction of 4-1BBL transcription and
cell surface expression by TSA, SAHA and MS-275, only MS-275
potentiated IFNc secretion in mixed leukocyte reactions and also
provided more efficient T lymphocyte proliferative responses in
these assays. These results suggest that compared to TSA and
SAHA, MS-275 can provide additional specific signalling to
improve further immune responses. Previous reports have shown
that HDACi can induce the expression of CD86/B7.2 costimu-
latory molecule in acute myeloid leukemia (AML) cells and freshly
isolated AML clinical samples [19]. Taken together with our
present finding that HDACi can enhance expression of yet
another costimulatory molecule, 4-1BBL, this data further
supports HDACi, especially MS-275, as antitumor drugs to be
used in immunotherapeutic clinical approaches. HDACi have
been shown to induce growth arrest, differentiation, and/or
apoptosis of cancer cells in vitro and in vivo tumor-bearing animals
models [13,63,64]. In association with the proapoptotic effect of
HDACi, the enhancement of costimulatory molecules on leukemia
blasts could augment tumor immunogenicity, increasing specific
CTL activity against tumor cells. Combinatorial treatment
modulating both apoptotic and costimulatory molecules may be
more effective for reinforcing host immunity and eradicating
tumors. This point is supported by a recent study by Uno et al.
who showed that induction of tumor cell apoptosis by an agonistic
antibody to TRAILR2/DR5, combined with T cell activation by
CD40 and 4-1BB agonistic monoclonal antibodies, potently and
rapidly stimulated tumor-specific CD8
+ T cells capable of
eradicating pre-established tumors [65]. It is noteworthy that
HDACi treatment did not induce 4-1BBL transcription in breast-
derived tumor cells lines, nor did it induce significant 4-1BBL
transcription in primary human peripheral blood lymphocytes,
suggesting leukemia specific modulation of 4-1BBL by HDACi
treatment (BV, data not shown).
In conclusion, we have demonstrated that HDACi can
modulate the expression of 4-1BBL costimulatory molecule in B
leukemia cell line model, which can enhance T cell responses
towards the tumor cells. Further studies are now required to
examine these effects using primary cells from patients with
chronic lymphocytic leukemia (CLL) and to determine in animal
models whether 4-1BBL/TNFSF9 up-regulation contributes to
Regulation of 4-1BBL by HDACi
PLoS ONE | www.plosone.org 12 September 2009 | Volume 4 | Issue 9 | e7085HDACi-induced anti-tumor effects in vivo. The distinct capacity of
MS-275 as compared to other HDACi to modulate these T cell
responses will also require further investigation.
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